Amphastar Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Amphastar Pharmaceuticalsの CEO はJack Zhangで、 Jan1996年に任命され、 の在任期間は 30.33年です。 の年間総報酬は$ 8.31Mで、 11.4%給与と88.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の6.06%を直接所有しており、その価値は$ 48.27M 。経営陣と取締役会の平均在任期間はそれぞれ12.5年と6.9年です。
主要情報
Jack Zhang
最高経営責任者
US$8.3m
報酬総額
| CEO給与比率 | 11.44% |
| CEO在任期間 | 30.3yrs |
| CEOの所有権 | 6.1% |
| 経営陣の平均在職期間 | 12.5yrs |
| 取締役会の平均在任期間 | 6.9yrs |
経営陣の近況
Recent updates
分析記事 • May 15
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
The most recent earnings report from Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) was disappointing for...
ナラティブの更新 • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.ナラティブの更新 • Apr 10
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.ナラティブの更新 • Mar 26
AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.
ナラティブの更新 • Mar 12
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.ナラティブの更新 • Feb 26
AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.ナラティブの更新 • Feb 09
AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.ナラティブの更新 • Jan 25
AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.ナラティブの更新 • Jan 11
AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.ナラティブの更新 • Dec 13
AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.分析記事 • Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 7.6x might make it look like a...分析記事 • Apr 04
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 19
Amphastar Pharmaceuticals: A Gradual Strategy
Summary Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. My strategy includes a 0.75x position weight and a gradual approach combining the stock with a Covered Call. Read the full article on Seeking Alpha分析記事 • Jan 03
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 16
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.9x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...分析記事 • Nov 28
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Oct 25
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Summary Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in 2026, limiting long-term revenue potential. BAQSIMI contributed $38.5 million in Q2 2024 sales, affirming its strategic acquisition from Eli Lilly. Amphastar’s heavy reliance on a few high-margin products, like glucagon and epinephrine, may limit future growth due to rising competition. I recommend holding Amphastar as current valuations seem fair, but growth prospects are uncertain due to product competition and patent expirations. Read the full article on Seeking Alpha分析記事 • Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 14.1x might make it look like a...Seeking Alpha • Sep 12
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Summary Amphastar Pharmaceuticals has seen significant growth since its 2014 IPO, with its stock price increasing over 500% to $45 per share. The acquisition of Baqsimi from Eli Lilly is a key revenue driver, but its long-term profitability remains uncertain due to milestone payments. Amphastar's revenue growth from epinephrine and Primatene Mist may not be sustainable, and the company faces intense competition in these markets. The pipeline's future is unclear, with several FDA rejections and no standout products, leading to a "Hold" rating on Amphastar stock. Read the full article on Seeking Alpha
新しいナラティブ • Sep 10
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.分析記事 • Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 01
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Summary AMPH has materially benefited from a variety of temporary factors across their key product lines that have largely gone unnoticed by investors, sending shares up ~100% over the last 3yrs. Amphastar’s glucagon business has benefited from shortages at Fresenius, which were recently rectified. Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, a newly approved competitor ramps, and two potential competitors gain approval. The sole Orange Book patent on Primatene MIST, a key high margin product, expires in January 2026, which opens the door to material competition. Primatene is one of the few DTC products in its aisle without a generic. A handful of smaller “Other” products have been buoyed by a tornado which took out competitor Pfizer’s product warehousing. The magnitude of the benefit is larger than investors believe, and Pfizer is quickly returning to market. Read the full article on Seeking Alpha分析記事 • May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Seeking Alpha • May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Summary Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors. Read the full article on Seeking AlphaSeeking Alpha • May 15
Reassessing Amphastar Pharmaceuticals
Summary Amphastar Pharmaceuticals, Inc. stock is down approximately 30% this year, and the company reported mixed Q1 results last week. Despite the poor performance of the stock so far in 2024, there are some positives on the company and its stock. An updated analysis around Amphastar Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 04
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Summary Amphastar Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products, with a focus on strategic acquisitions. The company's portfolio includes high-margin products such as Primatene MIST and Glucagon Injection for severe hypoglycemia. Amphastar's pipeline includes promising upcoming products such as Rextovy, and its recent acquisition of Baqsimi enhances its position in diabetes management. AMPH's financials indicate manageable debt levels and the potential for continued revenue growth and profitability, reinforcing its investment appeal. My valuation analysis suggests AMPH is undervalued compared to peers, with strong business fundamentals supporting a "Strong Buy" rating. Read the full article on Seeking Alpha分析記事 • Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
With a price-to-earnings (or "P/E") ratio of 21.4x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...分析記事 • Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$79m |
| Dec 31 2025 | US$8m | US$951k | US$98m |
| Sep 30 2025 | n/a | n/a | US$112m |
| Jun 30 2025 | n/a | n/a | US$135m |
| Mar 31 2025 | n/a | n/a | US$142m |
| Dec 31 2024 | US$8m | US$915k | US$160m |
| Sep 30 2024 | n/a | n/a | US$158m |
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
報酬と市場: Jackの 総報酬 ($USD 8.31M ) は、 US市場 ($USD 3.79M ) の同規模の企業の平均を上回っています。
報酬と収益: Jackの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Jack Zhang (78 yo)
30.3yrs
在職期間
US$8,309,350
報酬
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 30.3yrs | US$4.03m | 2.53% $ 20.1m | |
| Co-founder | 30.3yrs | US$8.31m | 6.06% $ 48.3m | |
| CFO, Executive VP of Finance | 12.1yrs | US$3.24m | 0.17% $ 1.3m | |
| Executive VP of Sales | 12.9yrs | US$2.04m | 0.15% $ 1.2m | |
| Senior EVP of Production & EVP of Scientific Affairs | 10.9yrs | US$2.54m | 0.47% $ 3.8m | |
| Senior Vice President of Human Resources & Corporate Communication | 3.8yrs | データなし | データなし | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | データなし | データなし |
12.5yrs
平均在職期間
66yo
平均年齢
経験豊富な経営陣: AMPHの経営陣は経験豊富で経験豊富です（平均在職期間は12.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 30.3yrs | US$4.03m | 2.53% $ 20.1m | |
| Co-founder | 30.3yrs | US$8.31m | 6.06% $ 48.3m | |
| CFO, Executive VP of Finance | 3.8yrs | US$3.24m | 0.17% $ 1.3m | |
| Executive VP of Sales | 3.8yrs | US$2.04m | 0.15% $ 1.2m | |
| Lead Independent Director | 24.3yrs | US$377.50k | 0.068% $ 543.5k | |
| Independent Director | 4.9yrs | US$340.00k | 0.0062% $ 49.1k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 6.9yrs | US$327.75k | 0.042% $ 336.9k |
6.9yrs
平均在職期間
66.5yo
平均年齢
経験豊富なボード: AMPHの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 01:48 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Amphastar Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Pavan Patel | BofA Global Research |